facebook loader
Home Page > RSS
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.—ALL NEWS
You are viewing a feed that contains frequently updated content. When you subscribe to a feed, it is added to the Common Feed list. Updated information from the feed is automatically downloaded to your computer and can be viewed in Internet Explorer and other programs. Learn more about feeds.

Johnson & Johnson to Participate in 2013 Leerink Swann Global Health Care Conference(Feb 6, 2013)

Wed, 6 Feb 2013 11:14:53 EST
New Brunswick, NJ (Feb. 6, 2013) -- Johnson & Johnson (NYSE: JNJ) will participate in the 2013 Leerink Swann Global Health Care Conference on Wednesday, Feb. 13, at The Waldorf Astoria in New York, NY.  Joaquin Duato, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 1:30 p.m. (Eastern).....

Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article(Feb 5, 2013)

Tue, 5 Feb 2013 09:22:36 EST
TITUSVILLE, N.J., Feb. 5, 2013 /PRNewswire/ -- Janssen Research & Development, LLC, ("Janssen") announced today the publication of a new article that addresses integrated approaches to healthcare solutions. The authors challenge the healthcare industry to expand its thinking beyond product-focused, "magic bullet" drug development and discuss the need for an integrated approach to patient care, including use of devices, tools and services to help a patient's progress. The commentary, "Beyond magic bullets: true innovation in health care," was published in the February 2013 issue of  and is available at: .....

Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life-Science Start-Ups(Feb 5, 2013)

Tue, 5 Feb 2013 08:45:58 EST
SAN DIEGO, Ca February 5, 2013—Janssen Labs at San Diego, part of Janssen Research & Development, LLC (Janssen), today announced the addition of a Concept Lab and an Open Collaboration Space. The Concept Lab is a shared laboratory that offers entrepreneurs affordable access to single bench spaces to perform early stage research before committing additional capital. The Open Collaboration Space is an open-plan office setting that provides companies and individuals with desk space in an environment that facilitates interactions with other life-science entrepreneurs.  With these additions, Janssen Labs can now accommodate more than double the number of companies as when it opened.....

XARELTO® to be Studied with Factor Xa Inhibitor Antidote(Feb 5, 2013)

Tue, 5 Feb 2013 08:07:50 EST
RARITAN, NJ, February 5, 2013– Janssen Pharmaceuticals, Inc. (Janssen) today announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. and Bayer HealthCare to evaluate the safety of PRT4445 – an investigational-stage antidote for Factor Xa inhibitors – in healthy volunteers who have been administered the oral anticoagulant XARELTO® (rivaroxaban). The study will evaluate several dosage strengths of PRT4445 and its ability to reverse the anticoagulant activity of XARELTO® in emergency situations.....

Ethicon Receives 510(K) Clearance for ENSEAL® G2 Articulating(Feb 4, 2013)

Mon, 4 Feb 2013 09:35:23 EST
CINCINNATI, Ohio – February 4, 2013 – To address surgeons’ need for strong sealing in tight spaces where access is limited, Ethicon Endo-Surgery, Inc. (Ethicon) today announces the 510(k) clearance from the U.S. Food and Drug Administration for the ENSEAL G2 Articulating Tissue Sealer.  ENSEAL G2 Articulating is the first articulating advanced energy device designed to allow surgeons to take a perpendicular approach to seal vessels up to 7mm in diameter and lymphatics through a 5mm port.  Vessels sealed perpendicularly are stronger than those sealed at oblique angles.* Stronger sealing helps reduce the likelihood of internal bleeding and post-surgery complications. .....

Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment(Jan 22, 2013)

Tue, 22 Jan 2013 08:49:11 EST
NEW YORK (Jan. 22, 2013)Johnson & Johnson will present its Medical Devices & Diagnostics (MD&D) business strategy for accelerating growth during its annual Business Review today.  The presentations will focus on its market leading products, plans for global expansion and meaningful innovations in MD&D that position the company well for long-term growth in a dynamic market. Johnson & Johnson last highlighted its MD&D business in 2010.....

Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results(Jan 22, 2013)

Tue, 22 Jan 2013 07:14:31 EST
New Brunswick, NJ (January 22, 2013) – Johnson & Johnson today announced sales of $17.6 billion for the fourth quarter of 2012, an increase of 8.0% as compared to the fourth quarter of 2011. Operational results increased 9.3% and the negative impact of currency was 1.3%. Domestic sales increased 6.8%, while international sales increased 8.9%, reflecting operational growth of 11.2% and a negative currency impact of 2.3%. Sales for the fourth quarter of 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 5.6% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business. Worldwide sales for the full-year 2012 were $67.2 billion, an increase of 3.4% versus 2011. Operational sales increased 6.1% and the negative impact of currency was 2.7%.  Domestic sales increased 3.2%, while international sales increased 3.5%, reflecting operational growth of 8.4% and a negative currency impact of 4.9%. Sales for the full-year 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 3.1% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.....

Cordis Corporation Announces Two-Year Results from the STROLL Trial(Jan 21, 2013)

Mon, 21 Jan 2013 07:22:28 EST
Bridgewater, New Jersey – January 21, 2013 – Cordis Corporation today announced the presentation of the two-year STROLL study results at the Abstracts and Late Breaking Clinical Trials session at ISET 2013.....

Biosense Webster Showcases Cutting Edge Innovation At Boston AF 2013(Jan 18, 2013)

Fri, 18 Jan 2013 10:26:25 EST
Diamond Bar, CA – January 18, 2013 – Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase its portfolio of cutting edge innovative technologies at the 2013 Boston AF meeting. Boston AF, now in its 18 year, provides a scientific forum for health care professionals to learn about advances in research and therapeutics in the field of atrial fibrillation.....

Veridex and LabCorp Agreement Brings CellSearch CTC Test to China(Jan 17, 2013)

Thu, 17 Jan 2013 11:47:39 EST
Raritan, NJ – January 17, 2013 – Veridex, LLC today announced an agreement with LabCorp Clinical Trials that makes the CELLSEARCH®circulating tumor cell (CTC) test available for researchers conducting clinical trials in China.  This marks the first clinical reference laboratory in China that offers CTC testing and comes on the heels of China’s State Food & Drug Administration approval of CELLSEARCH® as an diagnostic to manage patients with metastatic breast cancer. .....